Mineralys Therapeutics Closes $118 Million Oversubscribed Series B Financing to Advance the Development of Novel, Targeted Treatment for Hypertension

by Ysios Capital

The round was led by RA Capital Management and Andera Partners. Additional new investors included RTW Investments, Rock Springs Capital, SR One Capital Management, Sectoral Asset Management, Ysios Cap...

Read more

Minoryx raises €51 million in a round co-led by Columbus Venture Partners and Caixa Capital Risc to support Marketing Authorization Application and launch preparations for X-linked Adrenoleukodystrophy (X-ALD) therapy

by Caixa Capital Risc

The round was co-led by Columbus Venture Partners and Caixa Capital Risc. Dr. Damià Tormo, representing Columbus Venture Partners, has joined Minoryx’s Board of Directors. CDTI, through its Innvier...

Read more

NorthSea Therapeutics Completes US$80 Million Series C Fundraising co-led by Ysios Capital to Advance Clinical Programs in Metabolic Disorders

by Ysios Capital

The financing round was co-led by Ysios Capital and Forbion Growth and joined by new investors; a large managed care organization, and Hercules Capital, Inc. Existing investors Forbion Ventures, venBi...

Read more

Vifor Pharma to acquire Sanifit, supported, among other investors, by Ysios Capital, Caixa Capital Risc, Columbus Venture Partners and Alta Life Sciences

by Caixa Capital Risc

Under the terms of the acquisition agreement, Vifor Pharma will acquire 100% of the outstanding shares in Sanifit Therapeutics, receiving full global rights for SNF472, further enhancing the company

Read more

Ysios Capital’s portfolio company Aura Biosciences prices IPO on NASDAQ

by Ysios Capital

Ysios Capital, a leading Spanish biotechnology venture capital firm, has announced that its portfolio company Aura Biosciences Inc. has priced its initial public offering (IPO) and is trading on the N...

Read more

Ysios Capital achieves Certification under the Diversity VC Standard

by Ysios Capital

Ysios Capital, a leading European venture capital firm specialized in the biotechnology sector, announces today that it has been successfully certified under the Diversity VC Standard, a certification...

Read more

Ysios Capital closes its third fund at €216 million ($260 million)

by Ysios Capital

YBF III – Ysios’ largest fund to date – provides biotech ventures with the resources to develop novel and disruptive therapies for indications with high-unmet medical need, supporting pioneering...

Read more

Adcendo raises EUR 51 Million in Series A Financing led by Novo Holdings and Ysios Capital to Advance Novel Antibody-Drug Conjugates for Treatment of Cancers

by Ysios Capital

Adcendo, a biotech company developing antibody-drug conjugates (ADCs) for the treatment of cancers, today announced the successful closing of a EUR 51 million (US$ 62 million) Series A financing. The ...

Read more

Synendos Therapeutics Expands Series A to CHF 24 million with new investment. Ysios Capital joins other investors

by Ysios Capital

Synendos Therapeutics (Synendos), a biopharmaceutical company focused on restoring the natural functioning of the endocannabinoid system to treat Central Nervous System (CNS) disorders, announces an e...

Read more

Vivet Therapeutics, supported by Ysios Capital and Columbus Venture, closes an exclusive license option with Mirum Pharmaceuticals

by Ysios Capital

Vivet’s second gene therapy product, VTX-803 for PFIC3, received US and European Orphan Drug Designation in May 2020.Vivet is supported by international life science investors including Novartis Ven...

Read more

Aura Biosciences, supported by Ysios Capital, Announces Oversubscribed $80 Million Financing

by Ysios Capital

Aura Biosciences, a clinical-stage oncology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the closing of an oversubsc...

Read more

Splice Bio, backed by Ysios Capital, Asabys Partners and Caixa Capital Risc, appoints Jean-Philippe Combal as Chairman of the Board of Directors

by Caixa Capital Risc

Splice Bio, a gene therapy company based on technology developed in the Muir Lab at Princeton University, announced today that it has appointed JeanPhilippe Combal as Chairman of its Board of Director...

Read more
Subscribe to Directory
Write an Article

Highlight

Axon moves into Cloud Technology

by Axon Partners Group

cloud technology axon

Axon has exited Captronic, the latest in...

by Axon Partners Group

Axon has exited Captronic Systems, an Indian company that develops tes...

Photos Stream